$9.27
9.12% yesterday
Nasdaq, Jun 13, 10:15 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Stock price

$9.27
+1.09 13.33% 1M
+0.99 11.96% 6M
+1.54 19.92% YTD
-3.81 29.13% 1Y
-27.54 74.82% 5Y
-21.18 69.56% 10Y
-21.18 69.56% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.93 9.12%
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

Key metrics

Market capitalization $464.99m
Enterprise Value $197.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.26
P/S ratio (TTM) P/S ratio 2.97
P/B ratio (TTM) P/B ratio 1.69
Revenue growth (TTM) Revenue growth 80.68%
Revenue (TTM) Revenue $156.72m
EBIT (operating result TTM) EBIT $-157.36m
Free Cash Flow (TTM) Free Cash Flow $-86.94m
Cash position $267.87m
EPS (TTM) EPS $-3.06
P/E forward 9.40
P/S forward 1.47
EV/Sales forward 0.62
Short interest 14.60%
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a REGENXBIO, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
92%
Hold
8%

Financial data from REGENXBIO, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
157 157
81% 81%
100%
- Direct Costs 33 33
13% 13%
21%
124 124
151% 151%
79%
- Selling and Administrative Expenses 74 74
12% 12%
47%
- Research and Development Expense 207 207
10% 10%
132%
-141 -141
43% 43%
-90%
- Depreciation and Amortization 16 16
8% 8%
10%
EBIT (Operating Income) EBIT -157 -157
40% 40%
-100%
Net Profit -158 -158
39% 39%
-101%

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Positive
Seeking Alpha
8 days ago
REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA decision represents a significant catalyst for RGNX shares, offering a compelling pre-approval investment opportunity.
Neutral
PRNewsWire
9 days ago
RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measures Biomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated ages One new participant aged 2 years at dosing had expression level at 118.6% compa...
Neutral
PRNewsWire
12 days ago
Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial ROCKVILLE, Md.
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 353
Founded 2008
Website regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today